Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 5/20 | 0.40 |
| ▸ | SETDB1 | Q15047 | 1/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3654246 | 0.84 | CA1 (0.52) | CA1CA2CA9CA12KCNA5 | |
| SCHEMBL30159605 | 0.75 | KCNA5 (0.56) | CA1CA12KCNA5HDAC10HDAC6 | |
| SCHEMBL8018113 | 0.75 | KCNA5 (0.56) | CA1CA12KCNA5HDAC10HDAC6 | |
| SCHEMBL19126687 | 0.74 | KCNA5 (0.49) | CA1CA12KCNA5HDAC10HDAC6 | |
| SCHEMBL26696901 | 0.74 | RXFP1 (0.43) | CA1CA2CA9CA12KCNA5 | |
| SCHEMBL15177957 | 0.72 | KCNA5 (0.40) | KCNA5HDAC10HDAC6DRD2SETDB1 | |
| SCHEMBL29957744 | 0.72 | KCNA5 (0.49) | CA1CA12KCNA5HDAC10HDAC6 | |
| SCHEMBL3589707 | 0.71 | KCNA5 (0.41) | CA1CA12KCNA5HDAC10HDAC6 | |
| SCHEMBL21484230 | 0.71 | HDAC10 (0.42) | KCNA5HDAC10HDAC6KDM4AMEN1 | |
| SCHEMBL6990507 | 0.71 | DRD2 (0.48) | KCNA5DRD2KDM4ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9314468-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9314468-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| US-9314468-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2016-04-19 | — | — | US | disclosed |
| EP-2664618-A2 | Chemokine receptor modulators | Altiris Therapeutics (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-2262808-B1 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2013-08-14 | — | — | EP | disclosed |
| US-20130172330-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172330-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172330-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8338448-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-8338448-B2 | Chemokine receptor modulators | ALTIRIS THERAPEUTICS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2262808-A2 | CHEMOKINE RECEPTOR MODULATORS | Altiris Therapeutics (US) | 2010-12-22 | — | — | EP | disclosed |
| US-20100029634-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029634-A1 | Chemokine Receptor Modulators | ALTIRIS THERAPEUTICS, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2009121063-A2 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2009-10-01 | — | — | WO | disclosed |
| WO-2009121063-A2 | CHEMOKINE RECEPTOR MODULATORS | ALTIRIS THERAPEUTICS (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172330-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | CA1 3991/4885CA2 3334/4885CA9 3208/4885 |
| US-20100029634-A1 | Chemokine Receptor Modulators | CCR5, CXCR4, ACKR3 | CA1 3991/4885CA2 3334/4885CA9 3208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.